Insider Selling: DexCom, Inc. (NASDAQ:DXCM) Director Sells 1,000 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) Director Bridgette P. Heller sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $113.55, for a total transaction of $113,550.00. Following the completion of the transaction, the director now owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

DexCom Stock Up 0.1 %

DXCM traded up $0.11 on Tuesday, hitting $116.64. 2,191,912 shares of the company were exchanged, compared to its average volume of 2,896,639. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The company has a market cap of $46.39 billion, a price-to-earnings ratio of 75.25, a price-to-earnings-growth ratio of 2.83 and a beta of 1.22. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08. The firm has a 50-day moving average price of $126.63 and a two-hundred day moving average price of $125.99.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, beating the consensus estimate of $0.27 by $0.05. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The firm had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. On average, equities analysts predict that DexCom, Inc. will post 1.78 earnings per share for the current year.

Analyst Ratings Changes

DXCM has been the topic of several recent analyst reports. UBS Group raised their target price on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Royal Bank of Canada began coverage on shares of DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. Citigroup increased their price objective on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a report on Monday, June 10th. Finally, Redburn Atlantic started coverage on DexCom in a research report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target for the company. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $140.94.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Team Hewins LLC boosted its stake in DexCom by 3.4% in the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after acquiring an additional 83 shares during the period. Bleakley Financial Group LLC increased its stake in shares of DexCom by 1.3% in the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after acquiring an additional 87 shares during the last quarter. Stableford Capital II LLC increased its position in DexCom by 2.1% during the fourth quarter. Stableford Capital II LLC now owns 4,367 shares of the medical device company’s stock worth $563,000 after buying an additional 88 shares during the last quarter. D Orazio & Associates Inc. boosted its holdings in DexCom by 0.8% during the fourth quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock valued at $1,534,000 after acquiring an additional 93 shares during the period. Finally, Gulf International Bank UK Ltd lifted its stake in shares of DexCom by 0.3% in the first quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock valued at $4,448,000 after buying an additional 93 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.